Cambridge, UK, 13 September 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announces that non-executive director, Anker Lundemose, will step down from the board at the end of September to enable him to commit more time to his other roles, particularly as CEO of Mission Therapeutics.
The board is initiating a process to identify candidates for appointment to the board to support Abzena through its next phase of growth, particularly of its biomanufacturing offering in the US.
Separately today, Abzena has announced a business update ahead of its AGM being held at 10am today at the Group’s Cambridge office.
Ken Cunningham, Chairman of Abzena commented:
“I would like to thank Anker for all his service to Abzena as it has transformed, through acquisitions, financing rounds and IPO. The Group is now realising the synergistic benefits of its US businesses and is set for the next phase of development, becoming a preferred partner for biopharmaceutical services.”
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
• Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
• Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
• Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
• Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
For more information, please see www.abzena.com
For more information, please contact firstname.lastname@example.org